Clinical Trials Search Results

1.

Autologous Peripheral Blood Stem Cell Transplant in Treating Patients with Lymphoma

Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT 2004-24, NCI-2010-01414, 0508M72589, 2005LS048, UMN-2005LS048, UMN-0508M72589, UMN-MT2004-24, NCT00345865

2.

A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD

Status: Temporarily closed
Phase: Phase III, Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 471501, NCI-2016-01887, NCT02956122

3.

Double Cord Versus Haploidentical (BMT CTN 1101)

Status: Active
Phase: Phase III
Type: Treatment
Age: 18 to 70
Trial IDs: BMTCTN1101, NCI-2014-00307, 2U10HL069294-11, 5U24CA076518, 715, NCT01597778

4.

Tacrolimus and Methotrexate with or without Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host-Disease in Patients with Hematological Malignancy Undergoing Donor Stem Cell Transplant

Status: Active
Phase: Phase III
Type: Supportive care
Age: 70 and under
Trial IDs: CASE 6Z13, NCI-2013-01800, NCT01951885

5.

A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants

Status: Active
Phase: Phase III
Type: Prevention
Age: 18 and over
Trial IDs: CR107047, NCI-2016-00410, 2015-001630-21, 39039039STM4001, NCT02555878

6.

Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)

Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-204, NCI-2016-00839, 163337, 2015-005053-12, NCT02684292

7.

Transplantation of Ex Vivo Expanded, UCB-derived, Stem & Progenitor Cells vs. Unmanipulated UCB for HM Patients

Status: Active
Phase: Phase III
Type: Treatment
Age: 16 to 60
Trial IDs: GC P#05.01.020, NCI-2016-01518, NCT02730299

8.

Efficacy and Safety of Maribavir in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment

Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 12 and over
Trial IDs: SHP620-303, NCI-2016-01720, 2015-004725-13, NCT02931539

9.

Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Not specified
Trial IDs: 95-024, NCI-2017-00824, MSKCC-95024, NCI-V95-0685, P30CA008748, NCT00002663

10.

Alemtuzumab Before Donor Stem Cell Transplant in Treating Patients With Hematologic Diseases

Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 70 and under
Trial IDs: HIMSUM, NCI-2012-00639, NCT00058825

11.

Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma

Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: TNX-650.101, NCI-2010-00951, NCT00441818

12.

Autologous or Donor Cytotoxic T-Lymphocytes in Treating Patients with Epstein-Barr Virus-Positive Hematologic Malignancy

Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Any age
Trial IDs: ALCI, NCI-2012-00653, 9936-ALCI, H-9936, NCT00070226, NCT00671164, NCT00062868

13.

Low-Dose Donor Bone Marrow Transplant in Treating Patients with Hematologic Malignancies

Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 montha to 70
Trial IDs: J1055, NCI-2011-00377, NCT01203722

14.

Dasatinib in Treating Patients with Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Previously Treated with Autologous Stem Cell Transplant

Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA-180-381, NCI-2012-00767, 1203010693, 2011-203, NCT01609816

15.

Brentuximab Vedotin and Bendamustine Hydrochloride in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma

Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: AAAJ5050, NCI-2012-01926, NCT01657331

16.

Conventional and Regulatory T Cells in Treating Patients with Advanced Hematologic Malignancies Undergoing T Cell-Depleted Donor Stem Cell Transplant

Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 13 to 60
Trial IDs: BMT236, NCI-2011-03025, NCT01660607

17.

Inotuzumab Ozogamicin, Fludarabine Phosphate, Bendamustine Hydrochloride, and Rituximab before Donor Stem Cell Transplant in Treating Patients with Lymphoid Malignancies

Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: 2012-0265, NCI-2012-02072, NCT01664910

18.

Gemcitabine Hydrochloride, Clofarabine, and Busulfan before Donor Stem Cell Transplant in Treating Patients with Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 to 65
Trial IDs: 2012-0506, NCI-2012-02055, NCT01701986

19.

Lenalidomide and Romidepsin with or without Dexamethasone in Treating Patients with Recurrent or Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma, or Multiple Myeloma

Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 80
Trial IDs: 1112009392, NCI-2015-00921, NCT01742793

20.

Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: BP-HM-001, NCI-2013-00518, NCT01744223

21.

Azacitidine in Treating Patients Undergoing Matched Unrelated Stem Cell Transplant

Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 201303012, NCI-2012-03105, NCT01747499

22.

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients with Stage II-IV HIV-Associated Hodgkin Lymphoma

Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AMC-085, NCI-2013-00046, 085, 2014-003678-18, NCT01771107

23.

Methoxyamine and Temozolomide in Treating Patients with Relapsed Solid Tumors or Lymphomas

Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9483, NCI-2013-00877, 130118, P121184, 13-C-0118, NCT01851369

24.

Radiolabeled Monoclonal Antibody and Combination Chemotherapy before Stem Cell Transplant in Treating Patients with High-Risk Lymphoid Malignancies

Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2728.00, NCI-2013-01378, NCT01921387

25.

Pralatrexate and Romidepsin in Treating Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma

Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: AAAJ5656, NCI-2014-01986, NCT01947140

Clinical Trials Search Results

Results 1-25 of 283 for your search: